Protagenic Therapeutics Faces Delisting Concerns
Ticker: PTIXW · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | high |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, compliance
Related Tickers: PTIX
TL;DR
Protagenic Therapeutics might be delisted, major red flag!
AI Summary
Protagenic Therapeutics, Inc. filed an 8-K on January 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was on January 15, 2025. The company was formerly known as Atrinsic, Inc., New Motion, Inc., and MPLC, Inc.
Why It Matters
This filing indicates potential issues with Protagenic Therapeutics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a severe indicator of financial distress or non-compliance, posing a significant risk to investors.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer of the 8-K report
- January 15, 2025 (date) — Date of the earliest event reported
- January 16, 2025 (date) — Filing date of the 8-K
- Atrinsic, Inc. (company) — Former name of Protagenic Therapeutics
- New Motion, Inc. (company) — Former name of Protagenic Therapeutics
- MPLC, Inc. (company) — Former name of Protagenic Therapeutics
FAQ
What specific listing rule or standard has Protagenic Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Protagenic Therapeutics has failed to satisfy, only that a notice has been issued.
What is the potential consequence of failing to meet continued listing requirements?
Failure to meet continued listing requirements can lead to the delisting of the company's securities from the exchange.
When was the earliest event related to this notice of delisting?
The earliest event reported in the filing occurred on January 15, 2025.
Has Protagenic Therapeutics provided any details on how it plans to address the delisting concerns?
This specific 8-K filing is a notice and does not contain details on the company's plans to address the delisting concerns.
What was Protagenic Therapeutics' former name prior to its current identity?
Protagenic Therapeutics, Inc. was formerly known as Atrinsic, Inc., New Motion, Inc., and MPLC, Inc.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2025-01-15 18:51:40
Filing Documents
- form8-k.htm (8-K) — 42KB
- 0001493152-25-002448.txt ( ) — 259KB
- ptix-20250115.xsd (EX-101.SCH) — 4KB
- ptix-20250115_def.xml (EX-101.DEF) — 29KB
- ptix-20250115_lab.xml (EX-101.LAB) — 36KB
- ptix-20250115_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. Date: January 15, 2025 By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer 3